Comparative efficacy and safety of rosuvastatin versus atorvastatin after acute ischemic stroke or transient ischemic attack: A systematic review and exploratory meta-analysis.
Luis E Cueva-Cañola, Andrea C Beltran-De la Fuente, Diana I Ramírez Navarro et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and exploratory meta-analysis evaluated the efficacy and safety of rosuvastatin versus atorvastatin in patients following acute ischemic stroke (AIS) or transient ischemic attack (TIA). The analysis included five studies, revealing that rosuvastatin led to greater improvements in lipid and inflammatory markers, while rates of recurrent stroke and all-cause mortality were similar. Notably, rosuvastatin was linked to lower rates of hemorrhagic stroke.
Key findings
- Rosuvastatin showed greater improvements in lipid and inflammatory markers compared to atorvastatin.
- Rates of recurrent stroke and all-cause mortality were similar between rosuvastatin and atorvastatin.
- Rosuvastatin was associated with lower rates of hemorrhagic stroke.
- Rosuvastatin demonstrated more favorable composite cardiovascular outcomes.
Why it matters
Understanding the comparative effects of statins post-stroke is crucial for optimizing secondary prevention strategies. This study highlights potential differences in safety and efficacy that may influence treatment decisions in clinical practice.